Acromegaly screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Acromegaly}} | {{Acromegaly}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{AEL}} | ||
==Overview== | ==Overview== | ||
== Screening == | == Screening == |
Revision as of 18:58, 7 August 2017
Acromegaly Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Acromegaly screening On the Web |
American Roentgen Ray Society Images of Acromegaly screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Screening
- According to the endocrine society, screening for acromegaly by measurement of IGF-1 is recommended among patients with the clinical features of acromegaly. These features include the following:
- Enlarged hands and feet
- Change in the facial features
- Headache
- Increase sweating
- Paraesthesia
- Skin thickening
- Protrusion of the lower jaw
- Screening also is recommended in patients with associated conditions of acromegaly. Acromegaly is associated with different comorbidities so that screening is important in patients with these comorbidities which include:
- Diabetes Mellitus
- Carpal tunnel syndrome
- Arthritis
- Sleep apnea
- Hypertension